Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.
Latest From David Wallace
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.
US rivals to Narcan will face obstacles as they attempt to compete in the public interest market, Emergent’s CEO told the virtual J.P. Morgan Healthcare Conference.
An attack on Hikma’s skinny-label generic version of Vascepa by originator Amarin, claiming induced infringement of patents protecting a cardiovascular indication, has been dismissed in the US.
Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
The latest decision in US litigation with HEC Pharma over multiple sclerosis treatment Gilenya means that generics will be kept off the market for at least two years, according to originator Novartis.